DE69031951D1 - Transformation von tierischen Hautzellen mit hilfe von Partikeln - Google Patents

Transformation von tierischen Hautzellen mit hilfe von Partikeln

Info

Publication number
DE69031951D1
DE69031951D1 DE69031951T DE69031951T DE69031951D1 DE 69031951 D1 DE69031951 D1 DE 69031951D1 DE 69031951 T DE69031951 T DE 69031951T DE 69031951 T DE69031951 T DE 69031951T DE 69031951 D1 DE69031951 D1 DE 69031951D1
Authority
DE
Germany
Prior art keywords
cells
microprojectiles
transformation
help
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69031951T
Other languages
English (en)
Other versions
DE69031951T2 (de
Inventor
Stephen Johnston
R Williams
John Sanford
Sandra Mcelligott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Duke University
EIDP Inc
Original Assignee
Cornell Research Foundation Inc
EI Du Pont de Nemours and Co
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc, EI Du Pont de Nemours and Co, Duke University filed Critical Cornell Research Foundation Inc
Application granted granted Critical
Publication of DE69031951D1 publication Critical patent/DE69031951D1/de
Publication of DE69031951T2 publication Critical patent/DE69031951T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
    • C12M35/04—Mechanical means, e.g. sonic waves, stretching forces, pressure or shear stimuli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Sustainable Development (AREA)
  • Mechanical Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69031951T 1989-11-16 1990-11-13 Transformation von tierischen Hautzellen mit hilfe von Partikeln Expired - Lifetime DE69031951T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43784889A 1989-11-16 1989-11-16
PCT/US1990/006597 WO1991007487A1 (en) 1989-11-16 1990-11-13 Particle-mediated transformation of animal tissue cells

Publications (2)

Publication Number Publication Date
DE69031951D1 true DE69031951D1 (de) 1998-02-19
DE69031951T2 DE69031951T2 (de) 1998-08-13

Family

ID=23738164

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69031951T Expired - Lifetime DE69031951T2 (de) 1989-11-16 1990-11-13 Transformation von tierischen Hautzellen mit hilfe von Partikeln

Country Status (11)

Country Link
US (6) US6194389B1 (de)
EP (1) EP0500799B1 (de)
JP (2) JPH05503841A (de)
AT (1) ATE162219T1 (de)
AU (1) AU6964191A (de)
CA (1) CA2068863C (de)
DE (1) DE69031951T2 (de)
DK (1) DK0500799T3 (de)
ES (1) ES2113371T3 (de)
GR (1) GR3026594T3 (de)
WO (1) WO1991007487A1 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6867195B1 (en) 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
ES2113371T3 (es) 1989-11-16 1998-05-01 Univ Duke Transformacion de celulas epidermicas de tejidos animales con la ayuda de particulas.
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
JP3881689B2 (ja) * 1992-03-11 2007-02-14 パウダージェクト ヴァクシンズ，インコーポレイテッド 免疫不全ウイルス用の遺伝子ワクチン
AU2146092A (en) * 1992-05-28 1993-12-30 Scientific Dimensions Usa, Inc. Transgenic animal production with biolistically transformed spermatozoa
GB2282139A (en) * 1993-09-24 1995-03-29 Univ Reading Introducing DNA into the germ line of birds
US6995008B1 (en) 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
DE4416784A1 (de) * 1994-05-09 1995-11-30 Soft Gene Gmbh Methode zur Anreicherung von Zellen, die durch ballistischen Transfer modifiziert wurden
US7223739B1 (en) 1995-06-07 2007-05-29 Powderject Vaccines, Inc. Adjuvanted genetic vaccines
AU2814897A (en) * 1996-04-25 1997-11-12 T Cell Sciences, Inc. Method of isolating regulators of t cell activation
US6893664B1 (en) * 1996-06-17 2005-05-17 Powderject Research Limited Particle delivery techniques
US6294378B1 (en) * 1996-07-26 2001-09-25 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US6433154B1 (en) 1997-06-12 2002-08-13 Bristol-Myers Squibb Company Functional receptor/kinase chimera in yeast cells
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
DE69930294T2 (de) * 1998-10-19 2006-11-02 Powderject Vaccines, Inc., Madison Minimale promotoren und ihre verwendung
US6881723B1 (en) 1998-11-05 2005-04-19 Powderject Vaccines, Inc. Nucleic acid constructs
WO2000045792A1 (en) 1999-02-03 2000-08-10 Powderject Research Limited Hydrogel particle formulations
US7022320B1 (en) 1999-02-09 2006-04-04 Powderject Vaccines, Inc. Mycobacterium tuberculosis immunization
US20040234539A1 (en) * 1999-11-03 2004-11-25 Powderject Research Limited Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
US20040109874A1 (en) * 1999-11-10 2004-06-10 Powderject Vaccines, Inc. Induction of mucosal immunity by vaccination via the skin route
IL151097A0 (en) 2000-02-23 2003-04-10 Smithkline Beecham Biolog Tumour-specific animal proteins
GB0008494D0 (en) 2000-04-07 2000-05-24 Secr Defence Microprojectile delivery system
DE60135455D1 (de) 2000-05-16 2008-10-02 Univ Minnesota It einer mehrfachdüsenanordnung
JP2004513615A (ja) 2000-06-28 2004-05-13 コリクサ　コーポレイション 肺癌の治療および診断のための組成物および方法
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7414032B2 (en) * 2001-06-25 2008-08-19 Immunofrontier, Inc. Vaccine comprising a polynucleotide encoding an antigen recognized by a CD4+ helper T-cell and a polynucleotide encoding a tumor specific or associated antigen recognized by a CD8+ CTL
HUP0402259A3 (en) 2001-09-20 2010-01-28 Glaxo Group Ltd Vaccines
CA2476755C (en) 2001-12-17 2014-08-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
RU2389732C2 (ru) 2003-01-06 2010-05-20 Корикса Корпорейшн Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7892205B2 (en) * 2003-06-06 2011-02-22 Boston Scientific Scimed, Inc. Device and method for delivering micronized therapeutic agents in the body
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
WO2005070122A2 (en) * 2004-01-09 2005-08-04 Boards Of Regents, The University Of Texas System Mechanosensitive ion channels and methods of use
KR20070028547A (ko) * 2004-06-18 2007-03-12 리전츠 오브 더 유니버스티 오브 미네소타 바이러스에 감염되고 백신접종된 생물의 동정
EP1793849A2 (de) 2004-09-22 2007-06-13 GlaxoSmithKline Biologicals SA Immunogene zusammensetzung zur verwendung bei der impfung gegen staphylokokken
US7901711B1 (en) 2006-04-17 2011-03-08 Gp Medical, Inc. Nanoparticles for protein/peptide delivery and delivery means thereof
US8137697B1 (en) 2004-10-05 2012-03-20 Gp Medical, Inc. Nanoparticles for protein/peptide delivery and delivery means thereof
US7449200B2 (en) * 2006-04-17 2008-11-11 Gp Medical, Inc. Nanoparticles for protein/peptide delivery and delivery means
JP2008526229A (ja) * 2005-01-06 2008-07-24 ベニテック，インコーポレーテッド 幹細胞の維持のためのＲＮＡｉ剤
WO2006091459A2 (en) 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
CA2894069C (en) 2005-06-24 2019-02-26 Regents Of The University Of Minnesota Prrs viruses, infectious clones, mutants thereof, and methods of use
US20090081157A1 (en) 2006-01-09 2009-03-26 Richard Syd Kornbluth Immunostimulatory Combinations for Vaccine Adjuvants
US9108217B2 (en) 2006-01-31 2015-08-18 Nanocopoeia, Inc. Nanoparticle coating of surfaces
CA2637883C (en) 2006-01-31 2015-07-07 Regents Of The University Of Minnesota Electrospray coating of objects
EP2529761B1 (de) 2006-01-31 2017-06-14 Nanocopoeia, Inc. Oberflächenbeschichtung mit nanoteilchen
US8449915B1 (en) 2006-04-17 2013-05-28 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
WO2007136758A2 (en) * 2006-05-19 2007-11-29 Board Of Regents, The University Of Texas System Sirna inhibition of p13k p85, p110, and akt2 and methods of use
US9040816B2 (en) 2006-12-08 2015-05-26 Nanocopoeia, Inc. Methods and apparatus for forming photovoltaic cells using electrospray
CN101754682B (zh) 2007-05-16 2014-11-12 布里格姆妇女医院 突触核蛋白病的治疗
EP2215269B1 (de) 2007-10-15 2017-12-13 Admedus Vaccines Pty Limited Konstruktsystem und verwendungen dafür
US9207242B2 (en) 2008-10-09 2015-12-08 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
WO2010105096A2 (en) 2009-03-11 2010-09-16 University Of Massachusetts Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212)
EP2756845B1 (de) 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Verfahren und Zusammensetzungen für spezifische KRAS-Hemmung mit asymmetrischer Doppelstrang-RNA
US20120208750A1 (en) 2009-09-29 2012-08-16 Joslin Diabetes Center, Inc. Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis
MD4087C1 (ro) * 2010-02-10 2011-08-31 Государственный Университет Молд0 Procedeu chimico-catalitic de depunere a acoperirilor metalice
US8841269B2 (en) * 2010-02-23 2014-09-23 Creighton University Polynucleotides for use in treating and diagnosing cancers
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
WO2012177595A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
JP2014533953A (ja) 2011-11-17 2014-12-18 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 治療用ｒｎａスイッチ組成物及び使用方法
WO2013138118A1 (en) 2012-03-14 2013-09-19 The Regents Of The University Of California Treatment of inflammatory disorders in non-human mammals
US20160002316A1 (en) 2013-02-22 2016-01-07 Joslin Diabetes Center Serpins: methods of therapeutic beta-cell regeneration and function
EP2769732A1 (de) 2013-02-22 2014-08-27 Sanofi Serpine: Verfahren zur therapeutischen Beta-Zellen-Regeneration und Funktion
EP2851086A1 (de) 2013-09-20 2015-03-25 Sanofi Serpine: Verfahren zur therapeutischen ß-Zellen-Regeneration und Funktion
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
WO2016077382A2 (en) 2014-11-11 2016-05-19 Massachusetts Eye & Ear Infirmary Conjunctivitis vaccines
WO2016100401A1 (en) 2014-12-15 2016-06-23 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
WO2016154010A1 (en) 2015-03-20 2016-09-29 Makidon Paul Immunogenic compositions for use in vaccination against bordetella
CA2980337A1 (en) 2015-04-03 2016-10-06 University Of Massachusetts Oligonucleotide compounds for targeting huntingtin mrna
EP3277815B1 (de) 2015-04-03 2021-09-22 University of Massachusetts Oligonukleotidverbindungen zur behandlung von präeklampsie und anderen angiogenen erkrankungen
EP3292206B8 (de) 2015-05-07 2022-02-09 Takeda Pharmaceutical Company Limited Glucocerebrosidase gentherapie von morbus parkinson
CA2995110A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
JP2018535655A (ja) 2015-09-29 2018-12-06 アムジエン・インコーポレーテツド Ａｓｇｒ阻害剤
CA3005878A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
US10596248B2 (en) 2015-12-09 2020-03-24 Jingang Medicine (Australia) Pty Ltd Immunomodulating composition for treatment
CA3011894A1 (en) 2016-01-31 2017-08-03 University Of Massachusetts Branched oligonucleotides
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
CA3033368A1 (en) 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
US10443055B2 (en) 2016-12-22 2019-10-15 Beth Israel Deaconess Medical Center Compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancer
EP3664834A1 (de) 2017-08-11 2020-06-17 Dana Farber Cancer Institute, Inc. Verwendung eines botulinumtoxinmittels zur behandlung von plasmazellstörungen
US11821003B2 (en) 2017-08-14 2023-11-21 Sanford Burnham Prebys Medical Discovery Institute Cardiogenic mesoderm formation regulators
AU2018318074A1 (en) 2017-08-14 2020-02-27 University Of Georgia Research Foundation, Inc. Proteins having pneumococcal capsule degrading activity and methods of use
EP3703669A4 (de) 2017-11-01 2021-11-10 Dana-Farber Cancer Institute, Inc. Verfahren zur behandlung von krebs
CN112424352A (zh) 2018-05-11 2021-02-26 阿尔法阿诺麦里克公司 包括7′-5′-α-异头双环糖核苷的寡核苷酸缀合物
JP2021533762A (ja) 2018-08-10 2021-12-09 ユニバーシティ・オブ・マサチューセッツUniversity Of Massachusetts Ｓｎｐを標的化する修飾オリゴヌクレオチド
EP3843845A4 (de) 2018-08-29 2022-05-11 University Of Massachusetts Hemmung von proteinkinasen zur behandlung von friedreich-ataxie
BR112021012172A2 (pt) 2018-12-12 2021-08-31 Kite Pharma, Inc. Receptores de antígenos quiméricos e de célula t e métodos de uso
CN114072501A (zh) 2019-05-06 2022-02-18 马萨诸塞大学 抗c9orf72寡核苷酸及相关方法
WO2021195089A1 (en) 2020-03-23 2021-09-30 Sorrento Therapeutics, Inc. Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof
WO2022016035A1 (en) 2020-07-17 2022-01-20 University Of Georgia Research Foundation, Inc. Β-glucuronidase proteins having pneumococcal capsule degrading activity and methods of use
EP4359539A1 (de) 2021-06-23 2024-05-01 University Of Massachusetts Optimierte anti-flt1-oligonukleotidverbindungen zur behandlung von präeklampsie und anderen angiogenen erkrankungen

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7781E (fr) 1907-04-16 1907-10-11 Jacques Delpech Procédé ayant pour but de supprimer le tremblement apparent des projections cinématographiques
US3931397A (en) 1971-11-05 1976-01-06 Beecham Group Limited Biologically active material
GB1594097A (en) 1976-12-16 1981-07-30 Int Inst Of Differentiation Production of specific immune nucleic acids cell dialysates and antibodies
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
EP0091539B2 (de) 1982-03-31 1996-11-27 Ajinomoto Co., Inc. Das Polypeptid Interleukin-2 kodierendes Gen, rekombinante, dieses Gen enthaltende DNA, diese rekombinante DNA aufweisende Zelllinien und Verfahren zur Herstellung von Interleukin-2 unter Verwendung der genannten Zellen
US4798786A (en) 1982-05-06 1989-01-17 Stolle Research And Development Corporation Living cells encapsulated in crosslinked protein
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
NZ209840A (en) * 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
US4761375A (en) * 1984-05-08 1988-08-02 Genetics Institute, Inc. Human interleukin-2 cDNA sequence
WO1986000930A1 (en) 1984-07-20 1986-02-13 Worcester Foundation For Experimental Biology Retroviral vaccines and vectors and methods for their construction
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US4806463A (en) 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5015580A (en) 1987-07-29 1991-05-14 Agracetus Particle-mediated transformation of soybean plants and lines
IL84459A (en) 1986-12-05 1993-07-08 Agracetus Apparatus and method for the injection of carrier particles carrying genetic material into living cells
US4944942A (en) 1987-08-27 1990-07-31 Mobay Corporation Intranasal vaccination of horses with inactivated microorganisms or antigenic material
US4945000A (en) * 1989-01-18 1990-07-31 Btl Specialty Resins Corp. Particulate thermosetting adhesive compositions
ES2200016T3 (es) 1989-03-21 2004-03-01 Vical Incorporated Expresion de secuencias polinucleotidicas exogenas en un vertebrado.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ES2194834T3 (es) * 1989-06-26 2003-12-01 Powderject Vaccines Inc Transformacion por medio de particulas de celulas somaticas animales.
ES2113371T3 (es) * 1989-11-16 1998-05-01 Univ Duke Transformacion de celulas epidermicas de tejidos animales con la ayuda de particulas.
US5204253A (en) * 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
JPH09501936A (ja) * 1993-08-26 1997-02-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための方法、組成物および装置
US5703057A (en) * 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
WO1997019675A2 (en) 1995-11-30 1997-06-05 Vical Incorporated Complex cationic lipids
US5994317A (en) 1996-04-09 1999-11-30 Vical Incorporated Quaternary cytofectins

Also Published As

Publication number Publication date
ATE162219T1 (de) 1998-01-15
AU6964191A (en) 1991-06-13
US20020006637A1 (en) 2002-01-17
US20040170616A1 (en) 2004-09-02
CA2068863A1 (en) 1991-05-17
US20040097458A1 (en) 2004-05-20
JPH05503841A (ja) 1993-06-24
DE69031951T2 (de) 1998-08-13
US7358234B2 (en) 2008-04-15
EP0500799A4 (en) 1993-05-05
US20080138325A1 (en) 2008-06-12
EP0500799A1 (de) 1992-09-02
DK0500799T3 (da) 1998-09-14
US7449449B2 (en) 2008-11-11
US20040092019A1 (en) 2004-05-13
CA2068863C (en) 2009-06-02
EP0500799B1 (de) 1998-01-14
ES2113371T3 (es) 1998-05-01
JP2001103968A (ja) 2001-04-17
US6194389B1 (en) 2001-02-27
GR3026594T3 (en) 1998-07-31
WO1991007487A1 (en) 1991-05-30

Similar Documents

Publication Publication Date Title
DE69031951D1 (de) Transformation von tierischen Hautzellen mit hilfe von Partikeln
DE59611371D1 (de) Verfahren zur Herstellung von Erythropoietin frei von tierischen Proteinen
EP1225225A3 (de) Osteogene Vorrichtungen
LU90855I2 (en) Proteine 1 osteogenique recombinante humaine: bmp-7 et ses d-riv-s pharmaceutiquement acceptables
DE69632536D1 (de) Impfstoffe für das respiratorische-synzytial-virus mit nuklein säuren
DE3689447D1 (de) Rekombinantes Viren-Überzugsprotein assoziiert mit "Acquired Immune Deficiency Syndrome" (AIDS) und Verfahren zur Testung von AIDS.
ATE385810T1 (de) Verwendung von dna oder rna zur herstellung eines medikaments zur behandlung von tumoren
DE69230993T2 (de) Rekombinante viren vektoren zur expression in muskelzellen
DK288183D0 (da) Fremgangsmade til fremstilling af et oligonucleotidt terapeutisk middel
DK592186D0 (da) Fremgangsmaade til udvinding af proteiner
MA20411A1 (fr) Procede de preparation de polypeptides ayant l'activite du gamma-interferon humain
CA2290696A1 (en) Immunopotentiating composition
DE3864500D1 (de) Verfahren und anlage zum konditionieren von mit lebenden zellen beschichteten kunststofftraegern.
EP0375350A3 (de) Vinylpyridinium vernetztes Polymer
KR900002795A (ko) 하이브리드 단백질c 작제물 및 그들의 제조방법
DK610888D0 (da) Cardiodilatinfragmentet, fremgangsmaade til fremstilling deraf samt dets anvendelse
Vane et al. Genetic engineering and pharmaceuticals
KR890008317A (ko) 유전학적 조작에 의한 응고억제성 단백질 pp4의 제조방법
WO1994025590A3 (en) Trichohyalin and transglutaminase-3 and methods of using same
EP0315118A3 (de) Endothelin kodierendes DNA und dessen Verwendung
RU96122169A (ru) Нон-сплайсинговые варианты gp350/220
DE60032143D1 (de) Verwendung von eif4e-bindungsreagenzien in der therapie
HUP9702147A2 (hu) Humán DNáz I variánsok
DK0467839T3 (da) In-vitro-behandling af fusionsproteiner
KR880701249A (ko) 신규 단백질, 신경류킨

Legal Events

Date Code Title Description
8364 No opposition during term of opposition